Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeithROCO:6236 60 Net Margin % is 14.07% as of Dec. 2025. GuruFocus rates ROCO:6236 with a GF Score™ of 60/100 and a GF Value™ of NT$24.56 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Neith ranks better than 80.02% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Neith's Net Income for the
three
months ended in Dec. 2025 was NT$1.16 Mil. Neith's Revenue for the
three
months ended in Dec. 2025 was NT$8.27 Mil. Therefore, Neith's net margin for the quarter that ended in Dec. 2025 was 14.07%.
The historical rank and industry rank for Neith's Net Margin % or its related term are showing as below:
ROCO:6236'
s Net Margin % Range Over the Past 10 Years
Min: -100.33 Med: -34.37 Max: 8.74
Current: 8.74
ROCO:6236's Net Margin % is ranked better than 80.02% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs ROCO:6236: 8.74
Neith (ROCO:6236) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Neith Net Margin % Related Terms
Neith Net Margin % Historical Data
* Premium members only.
The historical data trend for Neith's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6236 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Neith's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neith Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neith's Net Margin % distribution charts can be found below:
* The bar in red indicates where Neith's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neith (ROCO:6236) has a Net Margin % of 14.07% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Neith and its competitors. According to the industry distribution chart, Neith ranks #188 out of 941 companies in the Biotechnology industry, placing it in the top 20%.
Is Neith's Net Margin % too high?
Neith's current Net Margin % is 14.07%. Based on the distribution chart, Neith ranks #188 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neith has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Neith's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neith ranks #188 out of 941 companies for Net Margin %. This places Neith in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Neith and its competitors. Neith's current Net Margin % is 14.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neith stock overvalued right now?
Based on GuruFocus' analysis, Neith (ROCO:6236) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.56, compared to a current price of NT$17.05 — trading 30.6% below its estimated fair value. The current Net Margin % is 14.07%. Neith's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Neith (ROCO:6236), the current Net Margin % is 14.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neith (ROCO:6236) Overvalued in 2026?
Based on GuruFocus' analysis, Neith stock appears to be undervalued.
The current stock price of NT$17.05 is trading 30.6% below its estimated GF Value™ of NT$24.56.
GuruFocus considers Neith to be Possible Value Trap.
Key valuation signals for ROCO:6236:
Net Margin %: 14.07%
GF Value™: NT$24.56 vs. price of NT$17.05 (30.6% below fair value)
No single metric tells the full story. See the ROCO:6236 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neith Corp operates as a biotechnology company in Taiwan. It is involved in the following business divisions such as biotechnology, medical cosmetics, and preventive medicine businesses.
60GF Score
Get the complete analysis for ROCO:6236
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6236 has been successfully added to your 
